Search research articles
Contact Us
Filters
Showing results (71-80 of 226) with videos related to
Page
of 23
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Charlene M Fares, Eliezer M Van Allen, Charles G Drake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J Small, N Simon Tchekmedyian, Brian I Rini, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 23, 2003
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]
Patricia A Taylor, Christopher J Lees, Sylvie Fournier, et al.
The Journal of Experimental Medicine
|
March 22, 2024
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype
Naveen Sharma, Xiaozhou Fan, Oluwatomisin T Atolagbe, et al.
The Journal of Experimental Medicine
|
August 30, 2008
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
Sergio A Quezada, Karl S Peggs, Tyler R Simpson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 5, 2005
Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection
P'ng Loke, Xingxing Zang, Lisa Hsuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2019
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers-Response
Anu Sharma, Sumit K Subudhi, Jorge Blando, et al.
Cancer Research
|
November 24, 2011
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy
Rebecca Waitz, Stephen B Solomon, Elena N Petre, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 28, 2008
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
Marcella Fassò, Rebecca Waitz, Yafei Hou, et al.
Blood
|
May 8, 2007
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells
Thomas Enzler, Silke Gillessen, Michael Dougan, et al.
Page
of 23
Search research articles
Search
Showing results (71-80 of 226) with videos related to
Sort By:
Page
of 23
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Charlene M Fares, Eliezer M Van Allen, Charles G Drake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J Small, N Simon Tchekmedyian, Brian I Rini, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 23, 2003
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]
Patricia A Taylor, Christopher J Lees, Sylvie Fournier, et al.
The Journal of Experimental Medicine
|
March 22, 2024
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype
Naveen Sharma, Xiaozhou Fan, Oluwatomisin T Atolagbe, et al.
The Journal of Experimental Medicine
|
August 30, 2008
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
Sergio A Quezada, Karl S Peggs, Tyler R Simpson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 5, 2005
Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection
P'ng Loke, Xingxing Zang, Lisa Hsuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2019
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers-Response
Anu Sharma, Sumit K Subudhi, Jorge Blando, et al.
Cancer Research
|
November 24, 2011
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy
Rebecca Waitz, Stephen B Solomon, Elena N Petre, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 28, 2008
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
Marcella Fassò, Rebecca Waitz, Yafei Hou, et al.
Blood
|
May 8, 2007
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells
Thomas Enzler, Silke Gillessen, Michael Dougan, et al.
Page
of 23